Start Your NewsReadery Pro FREE TRIAL!

Register and verify your email address to start your NewsReadery Pro FREE TRIAL today!

Login / Register

sciencedaily.com / Share Newsitem

View, share or embed this newsitem using the details below.
A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than doubled from 2022 to 2023.
Continue
Please wait ...